title: [What vascular events suggest a myeloproliferative disorder?].
abstract: Patients with polycethemia vera (PV) or essential thrombocythemia (ET) are at increased risk of arterial and venous thromboembolic events. Arterial ischemic complications occur in 24 to 43% of these patients, particularly those with cardiovascular risk factors (especially cigarette smoking). Non-atheromatous arterial thrombosis concerns all large and medium-sized vessels, particularly cerebral, limb, coronary and digestive arteries. Extensive complications have been described in patients with lower limb occlusive arteriopathy, particularly stent or bypass thrombosis, critical ischemia. Juvenile myocardial infarction or rapid postangioplasty coronary thrombosis may reveal certain myeloproliferative disorders, particularly ET. Venous thrombosis is more frequent in PV than in ET; superficial or deep venous thromboses are seen. Thromboembolic events occur in about 25-30% of the patients and account for one-third of the deaths. Mesenteric vein thrombosis, portal thrombosis, or suprahepatic vein thrombosis may occur in all myeloproliferative disorders, but the pathogenesis is not fully understood. Pulmonary hypertension may be the consequence of local thrombosis in the pulmonary vasculature or may be due to the high blood flow in the right heart cavities. Microvascular circulatory disturbance includes erythromelalgia, Raynaud's phenomenon, digital ischemia, acrocyanosis, blue toe syndrome, livedo reticularis, cutaneous ulcers or necrotic purpura. All these manifestations may precede the myeloproliferative disorder by several months.
authors.affiliation: Service de Médecine Interne, Hôpital Claude Huriez, CHRU, 59037 Lille Cedex.
authors.forename: E
authors.initials: E
authors.lastname: Hachulla
authors.forename: C
authors.initials: C
authors.lastname: Rose
authors.forename: N
authors.initials: N
authors.lastname: Trillot
authors.forename: M T
authors.initials: MT
authors.lastname: Caulier-Leleu
authors.forename: U
authors.initials: U
authors.lastname: Pasturel-Michon
mesh_terms: D000328:Adult; D000368:Aged; D000477:Alkylating Agents / Q000009:adverse effects / Q000627:therapeutic use; D001157:Arterial Occlusive Diseases / Q000209:etiology; D003430:Cross-Sectional Studies; D004916:Erythromelalgia / Q000209:etiology; D005260:Female; D006470:Hemorrhage / Q000209:etiology; D006801:Humans; D006918:Hydroxyurea / Q000009:adverse effects / Q000627:therapeutic use; D006976:Hypertension, Pulmonary / Q000209:etiology; D007511:Ischemia / Q000209:etiology*; D008297:Male; D008833:Microcirculation; D008875:Middle Aged; D009196:Myeloproliferative Disorders / Q000150:complications / Q000175:diagnosis*; D009203:Myocardial Infarction / Q000209:etiology; D010146:Pain / Q000209:etiology; D011087:Polycythemia Vera / Q000150:complications / Q000175:diagnosis; D011693:Purpura / Q000209:etiology; D012883:Skin Ulcer / Q000139:chemically induced / Q000209:etiology; D012907:Smoking / Q000009:adverse effects; D020521:Stroke / Q000209:etiology; D013920:Thrombocythemia, Essential / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy; D019851:Thrombophilia / Q000209:etiology*; D020246:Venous Thrombosis / Q000209:etiology
chemical_list: D000477:Alkylating Agents; D006918:Hydroxyurea